Currently, clinical trials of anti-CTLA-4 (ipilimumab) and anti-PD-1 (nivolumab) are being performed in patients with glioma, testing the safety, toxicities, and efficacy (78). The gene discussed is CTLA4; the disease is central nervous system cancer.